Iridex reports Q3 revenue of $12.5 million, up 8% year-over-year
Reuters
Nov 12, 2025
Iridex reports Q3 revenue of $12.5 million, up 8% year-over-year
Iridex Corporation reported third quarter 2025 revenue of $12.5 million, an 8.0% increase from $11.6 million in the same period of 2024. Revenue from the Cyclo G6 product family reached $3.5 million, up 13.0% year-over-year from $3.1 million. The company sold 14,900 Cyclo G6 probes compared to 13,600 a year earlier, and 30 Cyclo G6 Glaucoma Laser Systems versus 26 in the prior year quarter. Other revenue increased by $0.2 million to $2.2 million, mainly due to higher service revenue and sales of legacy products, partially offset by decreased royalties following patent expirations. As of September 27, 2025, cash and cash equivalents were $5.6 million, down $1.2 million for the quarter. Iridex expects to achieve positive adjusted EBITDA for the full year 2025 and anticipates cash flow breakeven in the fourth quarter.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRIDEX Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572772-en) on November 11, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.